]>
IRCT20170306032913N4 IRCT 2020-02-16 Iran University of Medical Sciences Comparison of response and toxicity of capecitabine and oxaliplatin chemotherapy regimen with taxol and carboplatin with radiotherapy in esophageal cancer patients Comparison of response and toxicity of capecitabine and oxaliplatin chemotherapy regimen with taxol and carboplatin with radiotherapy in esophageal cancer patients 2017-03-21 anticipated 70 Complete https://irct.ir/trial/44223 interventional Randomization: Not randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Blinding description: Patients are divided into two groups with two different chemotherapy regimens that are prescribed in combination with radiotherapy. The disadvantages are described in each group but patients in each group will not be aware of the other group's line therapy. It also analyzes data without any benefit or potential loss. 2 Chemoradiotherapy in esophageal cancer patients. Intervention 1: Control group of 35 esophageal cancer patients receiving weekly paclitaxel (75mg/m2) and carboplatin (AUC:2)regimen with 5 days a week radiotherapy ( total dose:45-50Gy). Intervention 2: The intervention group of 35 esophageal cancer patients receiving capcitabine( 625mg/m2 daily during radiotherapy) and weekly oxaliplatin (50 mg/m2) regimen with 5 days a week radiotherapy ( total dose:45-50Gy). Yes - There is a plan to make this available What will be shared: All patient documentation, including participants' personal information, will be shared after unidentifiable individuals, and the main outcome will include the extent of pathologic and clinical response and the extent of any of the listed complications will be shared When: Access started in 1399 To whom: The data will be available to researchers working in academic and scientific institutions Conditions: The information will be made available to researchers who want to continue to plan or compare results with other regimens. Where to obtain: Department of Radiotherapy, Firoozgar Hospital, Dr. Ali Reza Nikofar arnikoofar@gmail.com How to obtain: Visit to the Radiotherapy Department of Firoozgar Hospital and Dr. Nikoofar The applicant was provided with information for about a week Comments:
public Alireza Nikoofar
Department of Radiotherapy,Firooz Hospital,Valadi St,Valiasr Square,Tehran
Tehran Iran (Islamic Republic of) 1593748711 +98 21 8214 1792 arnikoofar@gmail.com Iran University of Medical Sciences scientific Alireza Nikoofar
Department of Radiotherapy,Firouzgar Hospital,Valadi St,Valiasr Square,Tehran
Tehran Iran (Islamic Republic of) 1593748711 +98 21 8214 1792 arnikoofar@gmail.com Iran University of Medical Sciences Iran (Islamic Republic of) Proper Performance Status. No severe dysphagia 40 years 80 years Both Age over 80. Cervical Esophageal involvement C15 Malignant neoplasm of esophagus Treatment - Drugs Treatment - Drugs Control group of 35 esophageal cancer patients receiving weekly paclitaxel (75mg/m2) and carboplatin (AUC:2)regimen with 5 days a week radiotherapy ( total dose:45-50Gy) The intervention group of 35 esophageal cancer patients receiving capcitabine( 625mg/m2 daily during radiotherapy) and weekly oxaliplatin (50 mg/m2) regimen with 5 days a week radiotherapy ( total dose:45-50Gy) Pathologic and clinical response to chemoradiotherapy with two different regimens in esophageal cancer patients. Timepoint: Evaluation of response rate after completion of chemoradiotherapy and evaluation and comparison of complications during treatment. Method of measurement: Postoperative pathology report. EUS re-report after chemoradiotherapy. Iran University of Medical Sciences Approved 2019-09-28 Ethics committee of Iran University of Medical Sciences Department of Radiotherapy,Firoozgar Hospital,Valadi Ave,Valiasr Square,Tehran Tehran Tehran Iran (Islamic Republic of)